• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一例因双侧肾梗阻导致尿毒症表现的ALK易位阳性肺癌。

An ALK translocation positive carcinoma of the lung presenting as uremia due to bilateral renal obstruction.

作者信息

Rosenberg Shilo, Katz Ran, Pode Dov, Gofrit N Ofer, Pizov Galina, Hovav Nechushtan

机构信息

Department of Urology, Hadassah-Hebrew University Medical Center Jerusalem, Israel.

出版信息

Can Urol Assoc J. 2013 Jul-Aug;7(7-8):E490-4. doi: 10.5489/cuaj.172.

DOI:10.5489/cuaj.172
PMID:23914266
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3713148/
Abstract

We describe an unusual presentation of metastatic lung adenocarcinoma as malignant retroperitoneal fibrosis (MRPF). The diagnostic challenge, due to the small solitary lung mass and absence of a discrete retroperitoneal mass, was overcome by diagnostic laparoscopy. Molecular analysis of tissue acquired was positive for ALK gene rearrangement. Treatment of the patient with crizotinib reversed MRPF. He was weaned off the nephrostomy tubes and is with stable renal function 11 months after diagnosis.

摘要

我们描述了一例转移性肺腺癌表现为恶性腹膜后纤维化(MRPF)的不寻常病例。由于肺部存在孤立性小肿块且腹膜后无明显肿块,诊断面临挑战,而诊断性腹腔镜检查克服了这一难题。对获取的组织进行分子分析显示ALK基因重排呈阳性。使用克唑替尼治疗该患者后,MRPF得到缓解。患者停用了肾造瘘管,诊断后11个月肾功能稳定。

相似文献

1
An ALK translocation positive carcinoma of the lung presenting as uremia due to bilateral renal obstruction.一例因双侧肾梗阻导致尿毒症表现的ALK易位阳性肺癌。
Can Urol Assoc J. 2013 Jul-Aug;7(7-8):E490-4. doi: 10.5489/cuaj.172.
2
Neuroendocrine phenotype as an acquired resistance mechanism in ALK-rearranged lung adenocarcinoma.神经内分泌表型作为ALK重排肺腺癌的一种获得性耐药机制。
Lung Cancer. 2016 Feb;92:15-8. doi: 10.1016/j.lungcan.2015.12.001. Epub 2015 Dec 4.
3
[Lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement].伴有表皮生长因子受体(EGFR)突变和间变性淋巴瘤激酶(ALK)重排的肺腺癌
Rev Mal Respir. 2017 May;34(5):576-580. doi: 10.1016/j.rmr.2016.08.002. Epub 2016 Sep 17.
4
Early pneumothorax as a feature of response to crizotinib therapy in a patient with ALK rearranged lung adenocarcinoma.ALK 重排肺腺癌患者对克唑替尼治疗的反应特征为早期气胸。
BMC Cancer. 2013 Apr 26;13:207. doi: 10.1186/1471-2407-13-207.
5
Ovarian metastasis from lung adenocarcinoma with ALK-positive rearrangement detected by next generation sequencing: A case report and literatures review.经下一代测序检测到的伴有ALK阳性重排的肺腺癌卵巢转移:一例报告及文献复习
Cancer Biol Ther. 2017 May 4;18(5):279-284. doi: 10.1080/15384047.2017.1310344. Epub 2017 Mar 31.
6
Characteristics and Response to Crizotinib in ALK-Rearranged, Advanced Non-Adenocarcinoma, Non-Small Cell Lung Cancer (NA-NSCLC) Patients: a Retrospective Study and Literature Review.ALK 重排阳性的晚期非腺癌非小细胞肺癌(NA-NSCLC)患者的特征及对克唑替尼的反应:一项回顾性研究和文献复习。
Target Oncol. 2018 Oct;13(5):631-639. doi: 10.1007/s11523-018-0592-z.
7
Response to crizotinib in a lung adenocarcinoma patient harboring EML4-ALK translocation with adnexal metastasis: A Case Report.携带EML4-ALK易位并伴有附件转移的肺腺癌患者对克唑替尼的反应:病例报告
Medicine (Baltimore). 2016 Jul;95(30):e4221. doi: 10.1097/MD.0000000000004221.
8
Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.克唑替尼和阿来替尼序贯治疗ALK重排阳性非小细胞肺癌患者的无进展生存期和总生存期
Clin Lung Cancer. 2016 Nov;17(6):528-534. doi: 10.1016/j.cllc.2016.05.001. Epub 2016 May 18.
9
A novel fusion gene in a patient with metastatic lung adenocarcinoma and its response to crizotinib: a case report.一名转移性肺腺癌患者的新型融合基因及其对克唑替尼的反应:病例报告。
J Int Med Res. 2021 Sep;49(9):3000605211044652. doi: 10.1177/03000605211044652.
10
Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.ALK 重排肺癌获得性克唑替尼耐药相关的遗传变化的异质性。
J Thorac Oncol. 2013 Apr;8(4):415-22. doi: 10.1097/JTO.0b013e318283dcc0.

引用本文的文献

1
Retroperitoneal Metastasis, with Marked Fibrosis, of Lung Adenocarcinoma after Afatinib Treatment: An Autopsy Case Report.阿法替尼治疗后肺腺癌伴显著纤维化的腹膜后转移:尸检病例报告。
Intern Med. 2020 Nov 15;59(22):2915-2919. doi: 10.2169/internalmedicine.4869-20. Epub 2020 Jul 28.

本文引用的文献

1
ALK in lung cancer: past, present, and future.ALK 在肺癌中的过去、现在和未来。
J Clin Oncol. 2013 Mar 10;31(8):1105-11. doi: 10.1200/JCO.2012.44.5353. Epub 2013 Feb 11.
2
Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies.鉴定结直肠癌和肺癌活检组织中的新型 ALK 和 RET 基因融合。
Nat Med. 2012 Feb 12;18(3):382-4. doi: 10.1038/nm.2673.
3
Carcinoembryonic antigen (CEA) as tumor marker in lung cancer.癌胚抗原(CEA)作为肺癌的肿瘤标志物。
Lung Cancer. 2012 May;76(2):138-43. doi: 10.1016/j.lungcan.2011.11.012. Epub 2011 Dec 6.
4
Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.从不吸烟的非小细胞肺癌患者中,携带 EGFR 或 KRAS 突变或 ALK 重排的患者具有独特的临床特征和结局。
Cancer. 2012 Feb 1;118(3):729-39. doi: 10.1002/cncr.26311. Epub 2011 Jun 30.
5
Metastatic ureteral involvement of non-small cell lung cancer.非小细胞肺癌的输尿管转移
Case Rep Med. 2011;2011:394326. doi: 10.1155/2011/394326. Epub 2011 Mar 30.
6
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.间变性淋巴瘤激酶抑制在非小细胞肺癌中的作用。
N Engl J Med. 2010 Oct 28;363(18):1693-703. doi: 10.1056/NEJMoa1006448.
7
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.携带EML4-ALK的非小细胞肺癌患者的临床特征及预后
J Clin Oncol. 2009 Sep 10;27(26):4247-53. doi: 10.1200/JCO.2009.22.6993. Epub 2009 Aug 10.
8
Retroperitoneal fibrosis.腹膜后纤维化
Lancet. 2006 Jan 21;367(9506):241-51. doi: 10.1016/S0140-6736(06)68035-5.
9
Hydronephrosis as a complication of adenocarcinoma of the lung.肾积水作为肺癌的一种并发症。
Anticancer Res. 2003 May-Jun;23(3C):2915-6.
10
Metastatic disease of the ureter: patterns of tumoral spread and radiologic findings.输尿管转移性疾病:肿瘤扩散模式及影像学表现
Abdom Imaging. 1993;18(1):88-94. doi: 10.1007/BF00201710.